DOCSLIB.ORG

Progesterone Use in Gynaecology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progesterone Use in Gynaecology Earn up to 3 free CEUs Women’s health Leader in digital CPD for Southern African healthcare professionals Progesterone use in gynaecology Introduction This expert review on the use and benefits of progesterone therapy in clinical gynaecological medicine provides clarity on the use of micronised progesterone in menopausal hormone therapy (MHT) and pregnancy loss. It provides an up-to-date expert assessment of the available progesterones in South Africa with guidance on their use in luteal phase deficiency, prevention of miscarriage or preterm birth, and in the treatment of menstrual abnormalities. KEY MESSAGES Dr Tobie de Villiers MB ChB, MMed (O&G), • Natural progesterone differs from the later development of so-called progestins which are synthetic derivatives FCOG (SA), FRCOG. of progesterone Consultant Gynaecologist • The development of synthetic progestins was accelerated by the findings of the Womens Health Initiative which Stellenbosch University highlighted the fact that unopposed oestrogen in MHT leads to endometrial hyperplasia and cancer and Panorama MediClinic, • In MHT, the beneficial breast cancer-reducing effect of oestrogen therapy alone is lost when combined with a Parow metabolically active progestin, such as medroxyprogesterone acetate. However, when combined with progesterone, [email protected] the increased risk of breast cancer and increased risk of venous thrombotic events (VTEs) is attenuated • Route of administration is important to reducing side effects • Supplementation of progesterone by oral or vaginal route is very effective for the normalisation of cycle length and the amount of menstrual bleeding. Progesterone is produced by the ovarian corpus both oestrogen and progesterone, with the luteum after ovulation in a normal menstrual resultant orderly shedding of the endometrium cycle. Progesterone transforms proliferative called menstruation. Absence of or deficiencies endometrium (oestrogen effect) into secretory in progesterone secretion in a cycle may lead endometrium. This prepares the endometrium to various gynaecological disorders that could for pregnancy implantation (Figure 1). Failure benefit from progesterone therapy. of pregnancy will lead to the withdrawal of ENDOMETRIAL CHANGES Menstruation Menstruation Day 1 Proliferation 12 Secretion Regression 28 OVARIAN HORMONES Oestrogen Progesterone Day 1 12 28 VASCULAR CHANGES This report was made possible by an unrestricted educational grant from Cipla. The content of the report is independent of the sponsor. Day 1 12 28 Figure 1. The menstrual cycle Amended from the Women’s Health Journal Online, April 2017. OCTOBER 2019 I 1 Progesterone use in gynaecology Brief historical perspective1 Different groups described the isolation and formulation of the corpus luteum hormone in 1931-1934. The name progesterone was coined in 1934 after the conversion of pregnanediol to progesterone was discovered. The synthesis of progesterone from cholesterol was described in 1939, followed in 1941 by the synthesis of progesterone from diosgenin (obtained from the bark of the Mexican yam tree) (Figure 2). Progesterone was initially restricted to intra- muscular administration, but the micronised Figure 2. The Mexican yam tree Source: Lehmann PA, Bolivar F, Quintero R. Russel E. Marker: form thereof, which has been available since Pioneer of the Mexican steroid industry. J Chemical Education 1980, enables oral administration. 1973; 50: 195-199. The progestogens Clinicians currently have available a group of Many progestogens have cross-reactivity with steroidal hormones with progestogenic action, receptors other than just the progesterone collectively called the progestogens. This receptor, meaning they may have agonist and/ group includes the natural progestogen, pro- or antagonist effects on oestrogen, androgen, gesterone; the retroprogesterone called dydro- glucocorticoid and mineralocorticoid recep- gesterone; several progesterone derivatives, tors. This could lead to unwanted side effects.3 including 17-hydroxyprogesterone derivatives The development of the synthetic proges- and 19-nortestosterone derivatives; as well as tins were accelerated by the discovery that a spironolactone derivative.2 unopposed (oestrogen only) menopausal hor- All but natural progesterone are regarded mone therapy (MHT) leads to endometrial “All but natural as synthetic drugs and are known as proges- hyperplasia and cancer and that prevention tins. Some of the synthetic progestins must is possible with the concomitant use of a pro- progesterone be metabolised before they can exert their gestogen. Progestogens are currently used in a are regarded as biological function. Although all the pro- variety of applications such as oral contracep- synthetic drugs gesterones exert effects on the progesterone tives, MHT and the treatment of endometrio- receptors, they differ not only in respect of sis. This review will focus on the use of natural and are known as their potency but also their hormonal profile. progesterone in clinical practice. progestins.“ Progesterone Retroprogesterone Progesterone Dydrogesterone Progesterone Testosterone derivatives 17-OH-progesterone 19-progesterone 19-progesterone derivates derivates derivates Estranes Gonanes Pregnane Nor-Pregnane • Lynestrenol • Norgestrel • Hydroxyprogesterone • Nomegestrole acetate • Levonorgestrel • Desogestrel caproate • Demegestone • Norethisterone • Gestodene • Hydroxyprogesterone • Promegestone • Norethisterone acetate • Norgestimate heptanoate • Nestorone • Ethinodiol diacetate • Gestonorone caproate • Trimegeston • Norgestrienone • Chlormadinone • Dienogest EARN FREE acetate Spirolactone • Medrogestone derivative CPD POINTS • Medroxyprogesterone acetate Drospirenone Join our CPD community at • Cyproterone acetate www.denovomedica.com Figure 3. Classification of progesterones and start to earn today! Available forms of progesterone Progesterone is available in South Africa as: progesterone) indicated for luteal phase 1. Micronised oral tablets (100mg) indicated support in infertility treatment (Cyclogest®) for use in MHT (Utrogestan®) 3. Vaginal gel 8% (90mg per application) indi- 2. Vaginal pessaries (200mg micronised cated for luteal phase support (Crinone®). 2 I OCTOBER 2019 Progesterone use in gynaecology Route of administation The local application of vaginal progester- breast exposure to progesterone as well as a one allows optimal delivery to the uterus with better side effect profile. In some countries, minimal doses and avoids the large number vaginal pessaries are also allowed to be applied of progesterone metabolites seen after oral rectally. It should be noted that progesterone administration because of the first-pass liver is poorly absorbed by the skin and the vaginal effect.4 Vaginal application allows for minimal gel should not be used transdermally. Clinical indications Menopausal hormone therapy (MHT) In the aftermath of the Women’s Health registered for MHT. Some concern, though, Initiative study, several principles were for- has been expressed that the endometrial sup- mulated to make MHT as safe as possible.5 pressive effect of systemic progesterone is The use of oestrogen alone lowers the risk less than that of the progestins.7 In 2016, an of breast cancer. This beneficial effect is lost expert panel of gynaecological endocrino- when oestrogen is opposed by a metabolically logists concluded that, when combined with active progestin such as medroxyprogester- oestrogens, oral MP provides endometrial one acetate. The increased risk of breast can- protection if applied sequentially for 12-14 cer and increased risk of venous thrombotic days/month at 200mg/day for up to five years. events (VTEs) associated with progestins Vaginal MP may provide endometrial protec- can be attenuated by combining oestrogen tion if applied sequentially for at least 10 days/ with natural progesterone.6 In South Africa, month at 4% (45mg/day) or every other day oral micronised progesterone (MP) 100mg at 100mg/day for up to 3-5 years.8 Long-term daily (continuous therapy) or 200mg daily safety and compliance have not been studied. for 10 days per month (sequential therapy) is Progesterone and pregnancy loss Appropriate levels of progesterone after ovula- pregnancy may lead to unique clinical presen- tion are important for successful implantation tations of failed pregnancy. These will be dis- and continuation of pregnancy. Inappropriate cussed below. low levels of progesterone at various stages of Luteal phase deficiency Luteal phase deficiency in natural cycles has (OR 1.77, CI 1.09-2.86) in the progesterone been recognised for many years. The advent group.9 Although some of the early pregnancy of ovulation induction, especially associated losses in IVF must be because of genetically with in vitro fertilisation (IVF) has highlighted abnormal embryos, a significant proportion is this condition. In IVF, progesterone produc- secondary to endometrial conditions. Routine tion is decreased secondary to supraphysi- progesterone support in IVF is the norm in ological levels of oestrogen as well as reduced most IVF units in South Africa, and vaginal granulosa cells secondary to ova harvesting. MP pessaries are registered for this purpose. A recent Cochrane meta-analysis comparing Their use may be started directly after ova progesterone support in IVF to placebo or harvesting or after positive pregnancy test. no treatment, showed a higher live-born rate Prevention of miscarriage Progestogens have controversially been used levels cannot be made
Load more

Recommended publications
  • Classification and Pharmacology of Progestins
    Maturitas 46S1 (2003) S7–S16 Classification and pharmacology of progestins Adolf E. Schindler a,∗, Carlo Campagnoli b, René Druckmann c, Johannes Huber d, Jorge R. Pasqualini e, Karl W. Schweppe f, Jos H. H. Thijssen g a Institut für Medizinische Forschung und Fortbildung, Universitätsklinikum, Hufelandstr. 55, Essen 45147, Germany b Ospedale Ginecologico St. Anna, Corso Spezia 60, 10126 Torino, Italy c Ameno-Menopause-Center, 12, Rue de France, 06000 Nice, France d Abt. für Gynäkologische Endokrinologie, AKH Wien, Währingergürtel 18-20, 1090 Wien, Austria e Institute de Puériculture26, Boulevard Brune, 75014 Paris, France f Abt. für Gynäkologie und Geburtshilfe, Ammerland Klinik, Langestr.38, 26622 Westerstede, Germany g Department of Endocrinology, Universitair Medisch Centrum Utrecht, P.O. Box 85090, 3508 AB Utrecht, The Netherlands Abstract Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydroges- terone), progesterone derivatives (i.e. medrogestone) 17␣-hydroxyprogesterone derivatives (i.e. chlormadinone acetate, cypro- terone acetate, medroxyprogesterone acetate, megestrol acetate), 19-norprogesterone derivatives (i.e. nomegestrol, promege- stone, trimegestone, nesterone), 19-nortestosterone derivatives norethisterone (NET), lynestrenol, levonorgestrel, desogestrel, gestodene, norgestimate, dienogest) and spironolactone derivatives (i.e. drospirenone). Some of the synthetic progestins are prodrugs, which need to be metabolized to become active compounds. Besides
    [Show full text]
  • 2011/097571 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date \i\ 11 August 2011 (11.08.2011) 2011/097571 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/22 (2006.01) A61P 11/06 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/573 (2006.01) A61P 11/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 29/00 (2006.01) A61P 37/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/023917 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 February 201 1 (07.02.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/302,325 8 February 2010 (08.02.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 13/021,950 7 February 201 1 (07.02.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant (for all designated States except US): EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, PRAIRIE PHARMACEUTICALS, LLC [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 1041 1 Motor City Drive, Suite 750, Bethesda, MD 20817 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (US).
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    PHARMACEUTICALS volume 100 A A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007).
    [Show full text]
  • The Treatment of Monophasic Cycles with the Retroprogesterone Ro 4-8347
    The treatment of monophasic cycles with the retroprogesterone Ro 4-8347 Autor(en): Taubert, H.-D. / Jürgensen, O. Objekttyp: Article Zeitschrift: Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften = Bulletin de l'Académie Suisse des Sciences Medicales = Bollettino dell' Accademia Svizzera delle Scienze Mediche Band (Jahr): 25 (1969) PDF erstellt am: 25.09.2021 Persistenter Link: http://doi.org/10.5169/seals-307794 Nutzungsbedingungen Die ETH-Bibliothek ist Anbieterin der digitalisierten Zeitschriften. Sie besitzt keine Urheberrechte an den Inhalten der Zeitschriften. Die Rechte liegen in der Regel bei den Herausgebern. Die auf der Plattform e-periodica veröffentlichten Dokumente stehen für nicht-kommerzielle Zwecke in Lehre und Forschung sowie für die private Nutzung frei zur Verfügung. Einzelne Dateien oder Ausdrucke aus diesem Angebot können zusammen mit diesen Nutzungsbedingungen und den korrekten Herkunftsbezeichnungen weitergegeben werden. Das Veröffentlichen von Bildern in Print- und Online-Publikationen ist nur mit vorheriger Genehmigung der Rechteinhaber erlaubt. Die systematische Speicherung von Teilen des elektronischen Angebots auf anderen Servern bedarf ebenfalls des schriftlichen Einverständnisses der Rechteinhaber. Haftungsausschluss Alle Angaben erfolgen ohne Gewähr für Vollständigkeit oder Richtigkeit. Es wird keine Haftung übernommen für Schäden durch die Verwendung von Informationen aus diesem Online-Angebot oder durch das Fehlen von Informationen. Dies gilt auch für Inhalte Dritter, die über dieses Angebot zugänglich sind. Ein Dienst der ETH-Bibliothek ETH Zürich, Rämistrasse 101, 8092 Zürich, Schweiz, www.library.ethz.ch http://www.e-periodica.ch Abteilung fiir gynäkologische Endokrinologie (Leiter: Prof. TT.-T). Taubert) der Universitälsfraueiiklinik, Frankfurt/Main (Direktor; Prof. 0. Käser) The Treatment of Monophasic Cycles with the Retroprogesterone Ro 4-8347 H.-l).
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Literature Review of Organic Chemicals of Emerging Environmental Concern in Use in Auckland December TR 2008/028
    Literature Review of Organic Chemicals of Emerging Environmental Concern in Use in Auckland December TR 2008/028 Auckland Regional Council Technical Report No.028 December 2008 ISSN 1179-0504 (Print) ISSN 1179-0512 (Online) ISBN 978-1-877483-69-1 Technical Report, first edition Reviewed by: Approved for ARC publication by: Name: Judy-Ann Ansen Name: Paul Metcalf Position: Team Leader Position: Group Manager Stormwater Action Team Environmental Programmes Organisation: Auckland Regional Council Organisation: Auckland Regional Council Date: 1 November 2008 Date: 1 October 2009 Recommended Citation: AHERNS, M., 2008. Review of Organic Chemicals of Potential Environmental Concern in Use in Auckland. Prepared by NIWA for Auckland Regional Council. Auckland Regional Council Technical Report 2008/028. © 2008 Auckland Regional Council This publication is provided strictly subject to Auckland Regional Council's (ARC) copyright and other intellectual property rights (if any) in the publication. Users of the publication may only access, reproduce and use the publication, in a secure digital medium or hard copy, for responsible genuine non-commercial purposes relating to personal, public service or educational purposes, provided that the publication is only ever accurately reproduced and proper attribution of its source, publication date and authorship is attached to any use or reproduction. This publication must not be used in any way for any commercial purpose without the prior written consent of ARC. ARC does not give any warranty whatsoever, including without limitation, as to the availability, accuracy, completeness, currency or reliability of the information or data (including third party data) made available via the publication and expressly disclaim (to the maximum extent permitted in law) all liability for any damage or loss resulting from your use of, or reliance on the publication or the information and data provided via the publication.
    [Show full text]
  • Progestagens for Human Use. Exposure and Hazard Assessment for the Aquatic Environment J.P
    Progestagens for human use. Exposure and hazard assessment for the aquatic environment J.P. Besse, J. Garric To cite this version: J.P. Besse, J. Garric. Progestagens for human use. Exposure and hazard assessment for the aquatic environment. Environmental Pollution, Elsevier, 2009, 157 (12), p. 3485 - p. 3494. 10.1016/j.envpol.2009.06.012. hal-00455636 HAL Id: hal-00455636 https://hal.archives-ouvertes.fr/hal-00455636 Submitted on 10 Feb 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Environmental Pollution, vol. 157, n° 12, doi : 10.1016/j.envpol.2009.06.012 1 Progestagens for human use, exposure and hazard assessment for 2 the aquatic environment 3 4 5 6 Reviewed version of manuscript ENVPOL-D-09-00080R1. 7 The abstract of this paper was evaluated and approved by Dr Wiegand. 8 9 10 Authors 11 12 Jean-Philippe BESSE a* 13 Jeanne GARRIC a** 14 15 a Unité Biologie des écosystèmes aquatiques. Laboratoire d’écotoxicologie, 16 Cemagref, 3bis quai Chauveau CP 220 69336 Lyon cedex 09, France 17 Tel.: +33 472208902 18 19 * first author 20 ** corresponding author. E-mail address: [email protected] 21 22 23 Capsule: 24 Gestagens exposure and hazard assessment for the aquatic environment.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PRODUCT INFORMATION Dydrogesterone Item No
    PRODUCT INFORMATION Dydrogesterone Item No. 20514 CAS Registry No.: 152-62-5 Formal Name: (9β,10α)-pregna-4,6-diene-3,20-dione O Synonym: NSC 92336 MF: C21H28O2 FW: 312.5 Purity: ≥98% H UV/Vis.: λmax: 287 nm H H Supplied as: A crystalline solid Storage: -20°C O Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Dydrogesterone is supplied as a crystalline solid. A stock solution may be made by dissolving the dydrogesterone in the solvent of choice. Dydrogesterone is soluble in organic solvents such as ethanol, acetonitrile, and methanol, which should be purged with an inert gas. The solubility of dydrogesterone in these solvents is approximately 1 mg/ml. Description Dydrogesterone is a synthetic progestogen that has no estrogenic, androgenic, glucocorticoid, or anabolic effects, although it is an agonist of progesterone receptors (EC50 = 12.3 nM) and an antagonist of 1,2 androgen, mineralocorticoid, and glucocorticoid receptors (IC50s = 28.6, 82.7, and 363 nM, respectively). Dydrogesterone protects against sound stress-induced abortion in mice when administered at a dose of 1.25 mg per animal prior to the stressor on day five of pregnancy.3 Formulations containing dydrogesterone have been used in hormone replacement therapy, in the treatment of menstrual disorders, and to prevent miscarriage. References 1. Coelingh Bennink, H.J. and Boerrigter, P.J. Use of dydrogesterone as a progestogen for oral contraception. Steroids 68(10-13), 927-929 (2003). 2. Rižner, T.L., Brožič, P., Doucette, C., et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0082876 A1 Messinger Et Al
    US 20070082876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0082876 A1 Messinger et al. (43) Pub. Date: Apr. 12, 2007 (54) NOVEL C18 MODIFIED RETROSTEROIDS Publication Classification AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS (51) Int. Cl. A6II 3/58 (2006.01) (75) Inventors: Joseph Messinger, Sehnde (DE); A 6LX 3/57 (2006.01) Heinrich-Hubert Thole, Hannover C07 43/00 (2006.01) (DE); Bettina Husen, Hannover (DE); C07J 5/00 (2006.01) Christiane Boecker, Hannover (DE); (52) U.S. Cl. ......................... 514/176; 514/177: 540/107; Maria Hinaje, Nancy (FR); Monika 552/574 Buchholz, Langenfeld (DE); Christoph Mark, Worms (DE); Vibhuti (57) ABSTRACT Klingler-Dabral, Griesheim (DE) Retrosteroidal compounds of formula I which act as proges Correspondence Address: terone receptor modulators, a method for their production, CROWELL & MORING LLP and pharmaceutical preparations containing these com INTELLECTUAL PROPERTY GROUP pounds. These compounds are preferably used for the treat P.O. BOX 143OO ment of benign gynecological disorders such as endometrio WASHINGTON, DC 20044-4300 (US) sis and uterine fibroids, as well as for female birth control (73) Assignee: Solvay Pharmaceuticals GmbH, Han and for hormone replacement therapy (HRT). nover (DE) (21) Appl. No.: 11/529,628 (22) Filed: Sep. 29, 2006 Related U.S. Application Data (60) Provisional application No. 60/722,689, filed on Sep. 30, 2005. (30) Foreign Application Priority Data Jul. 28, 2006 (EP)........................................ O6118O34.5 Antiluteolytic activity in guinea pigs 10 11 12 13 14 15 16 17 18 day post ovulationem - O - dydrogesterone - example 2 - Ar mifepristone -v- example 5 -- example 13 Patent Application Publication Apr.
    [Show full text]